Plain-English translation of NCT07601737 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This study is testing whether nimotuzumab—a targeted cancer drug—works better when combined with immunotherapy and chemotherapy before surgery for advanced head and neck cancer. About 182 patients will receive either the new medication combination followed by surgery, or surgery alone. Researchers want to see if the medication shrinks tumors before surgery and helps patients stay cancer-free longer.
Currently, surgery and radiation are standard treatments for advanced head and neck cancer, but many patients still experience cancer recurrence. This trial explores whether giving the new treatment before surgery can improve survival rates and reduce the chance that cancer will return.
You likely qualify if…
You likely don't qualify if…
If you join the treatment group, you will receive the new medication combination (given intravenously) on specific days over several weeks, followed by surgery. If you are in the comparison group, you will proceed directly to surgery. All participants will be followed for at least 2 years after the last patient enrolls in the study, with visits to monitor your health and check for cancer recurrence.
AI-generated summary from trial data · Jun 24, 2026 · Not medical advice
China